Comparative Pharmacology
Head-to-head clinical analysis: EPANED versus LEVOPHED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPANED versus LEVOPHED.
EPANED vs LEVOPHED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epaned contains enalapril maleate, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is a prodrug that is hydrolyzed to enalaprilat, which inhibits ACE, thereby reducing angiotensin II formation, decreasing vasoconstriction, aldosterone secretion, and sodium reabsorption.
Norepinephrine acts predominantly on alpha-1 adrenergic receptors to cause vasoconstriction and increase blood pressure. It also has beta-1 adrenergic receptor agonist activity, resulting in positive inotropic effects on the heart.
0.2 mg/kg intravenously over 5 minutes every 2 hours; typical adult dose 10-20 mg IV.
Initial dose: 8-12 mcg/min intravenously, titrate to desired blood pressure; typical maintenance: 2-4 mcg/min IV continuous infusion.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 10-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and 15-20 hours in severe impairment (CrCl <30 mL/min).
The terminal elimination half-life is approximately 2 minutes. The clinical effect is short-lived due to rapid reuptake and metabolism; continuous intravenous infusion is required for sustained effect.
Renal excretion of unchanged drug accounts for approximately 30-40% of elimination; biliary/fecal excretion accounts for 50-60% as metabolites and unchanged drug.
Norepinephrine is primarily metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Less than 5% is excreted unchanged in urine. Metabolites are excreted renally (approximately 80-95% as normetanephrine, vanillylmandelic acid, and other conjugates).
Category C
Category C
Vasopressor
Vasopressor